Have dulaglutide and pramlintide been studied together?

Only in one case report: in 2023, a woman with type 1 diabetes and obesity lost a further 12.8 kg (14.0% of her weight) over 7 months after adding dulaglutide and pramlintide to topiramate. No trial has tested the pair.

← Stacks

Pair page — what's published on the two together

Dulaglutide with Pramlintide

Q: What is the legal status of Dulaglutide and Pramlintide?

Dulaglutide: FDA approved. Prescribed by a doctor, made by a manufacturer. Pramlintide: FDA approved. Prescribed by a doctor, made by a manufacturer.

Studied together only in one case report: a woman with type 1 diabetes and obesity who added both drugs to topiramate.

Studied together: 1 case report (2023)
Dulaglutide: FDA approved · evidence: Controlled trials
Pramlintide: FDA approved · evidence: Controlled trials

Studied Together

Type 1 diabetes with obesity (Wong et al., 2023)

What was given — A 68-year-old woman with type 1 diabetes on an insulin pump, whose weight loss on topiramate 50 mg a day had stalled, added weekly dulaglutide (0.75 mg, raised to 4.5 mg over five months) and pramlintide 60 µg before meals three times a day. One of three cases in the report; the other two took semaglutide.
What it found — She lost a further 12.8 kg (14.0%) over 7 months, 21.2 kg (23.1%) in all; HbA1c went from 7.6% to 7.1% and her basal insulin from 22 to 20 units a day, with no rise in low blood sugars. She had tolerable nausea, including 2 episodes of vomiting.
Limits — A single case; she stayed on topiramate, so the extra loss cannot be credited to the pair alone.

No trial of pramlintide with dulaglutide turned up in PubMed, Europe PMC or ClinicalTrials.gov (searched October 3, 2026).

Each Compound's Evidence

What each has shown on its own, from its Kalios card. The full profiles carry the sources.

Dulaglutide

Evidence: Controlled trials. Trulicity: a weekly diabetes shot, not a weight-loss drug. Typical loss: 2–5 kg.

Pramlintide

Evidence: Controlled trials. Approved in 2005 for diabetics on insulin: three shots a day, boxed warning. Not a weight-loss drug.

Legal Status

Current Status — October 2026

Dulaglutide: FDA approved. Prescribed by a doctor, made by a manufacturer.

Pramlintide: FDA approved. Prescribed by a doctor, made by a manufacturer.

References

Wong G, Garner EM, Srivastava G. Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes. JCEM Case Rep. 2023;1(2):luad040. PMID: 37908483.

Last updated: October 3, 2026 | A literature lookup, not a recommendation to combine anything.